TSHA
Taysha Gene Therapies
$4.01
+$0.05 (+1.26%)Oct 26, 2026
Key metrics
The numbers that frame TSHA today
- Market cap
- $1.31B
- Gross margin
- 100%
- EV / Sales
- 165.3
- ROIC
- -260.2%
- Div yield
- 0%
- Debt / equity
- 0.1
- 52wk Low
- $3.46
- 52wk High
- $7.30
Growth
Revenue and earnings trend for TSHA
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about TSHA
Is Taysha Gene Therapies a good buy?
No. Taysha Gene Therapies has poor quality and weak momentum. Both signals point to a weaker setup. Growth looks poor. That could put pressure on the long-term business case. We think Taysha Gene Therapies is selling at a very high price.
What is the market capitalization of TSHA?
Taysha Gene Therapies's market capitalization is $1.31B.
What is the 52-week high for TSHA stock?
The 52-week high for Taysha Gene Therapies is $7.30. The current close of $4.01 is 45.1% below that high.
What is the 52-week low for TSHA stock?
The 52-week low for Taysha Gene Therapies is $3.46. The current close of $4.01 is 16.1% above that low.
Does TSHA stock pay dividends?
Taysha Gene Therapies does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for TSHA?
Taysha Gene Therapies's Debt / Equity ratio is 0.14.